CHMP positive opinion on Eylea will stir up EU AMD market
This article was originally published in Scrip
Experts on the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) are recommending that the European Commission gives marketing approval for Eylea (aflibercept) as a treatment of neovascular (wet) age-related macular degeneration (AMD). The recombinant anti-VEGF fusion protein has already been approved for the same indication by the FDA (scripintelligence.com, 21 November, 2011), Australia (March 2012) and Japan (scripintelligence.com, 4 September, 2012). Eylea is currently in a Phase III clinical study for wet AMD in China (scripintelligence.com, 29 November, 2011).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.